Taking everything into account, PULM scores 3 out of 10 in our fundamental rating. PULM was compared to 191 industry peers in the Pharmaceuticals industry. While PULM has a great health rating, there are worries on its profitability. PULM is valied quite expensively at the moment, while it does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -124.85% | ||
| ROE | -131.42% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -67 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 19.97 | ||
| Quick Ratio | 19.97 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:PULM (1/9/2026, 8:19:06 PM)
2.36
+0.01 (+0.43%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2871.33 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.82 | ||
| P/tB | 1.82 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -124.85% | ||
| ROE | -131.42% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 19.97 | ||
| Quick Ratio | 19.97 | ||
| Altman-Z | -67 |
ChartMill assigns a fundamental rating of 3 / 10 to PULM.
ChartMill assigns a valuation rating of 1 / 10 to PULMATRIX INC (PULM). This can be considered as Overvalued.
PULMATRIX INC (PULM) has a profitability rating of 0 / 10.
The financial health rating of PULMATRIX INC (PULM) is 7 / 10.
The Earnings per Share (EPS) of PULMATRIX INC (PULM) is expected to decline by -10% in the next year.